MEDTECH: Separating the wheat from the chaff

by Posted on

MedTech, which has historically been a defensive sector, has once again stood its ground even as broader markets have been rattled by the pandemic.

But, digging into the details throws up interesting trends: the resilience is underpinned by clear extremes.

Hence, leveraging the right opportunities assumes a greater importance and is critical to outperformance.

At the upcoming webinar, we will dissect these conflicting trends and share some interesting stock ideas that are best suited to win in a COVID-stricken world.

AlphaValue’s analysts on the sector, Sumit Sayal, Virendra Chauhan and Martin Schnee, Ph.D., just released a new strategy piece on European Medtech companies, including : BioMérieux, Qiagen, Sartorius Stedim, Sartorius, Getinge, and Siemens Healthineers.

Access to report : click here

Published by Research Team

Our team of 30 leading analysts covering 480 stocks across Europe including 60% of the Stoxx 600, use a proprietary valuation model to provide a disciplined, consistent research framework.